High risk/high priority: familial hypercholesterolemia--a paradigm for molecular medicine (Q34614367)

3 August 2017

1 reference

title

High risk/high priority: familial hypercholesterolemia--a paradigm for molecular medicine (English)

1 reference

3 August 2017

0 references

Herbert Schuster

1

1 reference

3 August 2017

1 April 2002

1 reference

Atherosclerosis. Supplements

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

4

1 reference

3 August 2017

27-30; discussion 30-2

1 reference

Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Discovering Genes for New Medicines

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

A receptor-mediated pathway for cholesterol homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

The challenge of integrating genetic medicine into primary care

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Heart attacks: gone with the century?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

Molecular medicine. The cholesterol quartet

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5688%2801%2900019-8

7 January 2021

10.1016/S1567-5688(01)00019-8

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11976074